Imatinib Resistance Mutation Analysis Test, Price, Normal Range | Sprint Diagnostics Hyderabad
Patient Preparing : No special preparation is needed for this test. Patients should continue with their normal routine and take any prescribed medications unless instructed otherwise by their healthcare provider.
The Imatinib Resistance Mutation Analysis (IRMA) or Mutation Detection in the ABL Kinase Domain is a crucial diagnostic test primarily used in the field of oncology. This test focuses on identifying specific mutations in the ABL Kinase Domain that can cause resistance to imatinib, a medication used to treat certain types of cancer, like chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).
Imatinib is designed to inhibit the BCR-ABL protein produced by the Philadelphia chromosome, an abnormality commonly found in these cancers. However, certain mutations in the ABL kinase domain can cause resistance to imatinib, rendering the treatment less effective or ineffective.
|Imatinib Resistance Mutation Analysis (IRMA) or Mutation detection in the ABL kinase domain
|No special preparation is needed for this test. Patients should continue with their normal routine and take any prescribed medications unless instructed otherwise by their healthcare provider.
|Price in Hyderabad
Why is the Imatinib Resistance Mutation Analysis important?
The IRMA test is essential in the management of cancers like CML and GISTs. It helps determine whether a patient has developed resistance to imatinib, a key therapeutic agent for these conditions. If resistance is detected, alternative treatment strategies can be pursued.
Is fasting necessary for this test?
No, fasting is not required for the IRMA test. The test is performed on a blood or bone marrow sample, so there are no dietary restrictions or preparations necessary.
Home Sample Collection
When should this test be performed?
This test is typically recommended when a patient who is receiving imatinib therapy for CML or GISTs does not respond to treatment as expected or when the disease progresses despite treatment.
What information does the Imatinib Resistance Mutation Analysis test provide?
The IRMA test detects the presence of specific mutations in the ABL Kinase Domain that can cause resistance to imatinib. This information is crucial for determining the most effective treatment approach for the patient.
How often should this test be performed?
The frequency of this test is dependent on the patient's response to imatinib therapy. If a patient shows signs of resistance or if the disease progresses despite treatment, the test may be ordered. The treating healthcare provider will make the final decision based on the patient's specific clinical scenario.
What are the normal values for this test?
The "normal" value for the IRMA test is the absence of mutations in the ABL kinase domain. The presence of such mutations indicates a resistance to imatinib.
What precautions should be taken before the test?
No special precautions are necessary for the IRMA test. Patients are advised to continue with their regular routine and diet unless their healthcare provider instructs otherwise.
What factors can affect the test results?
The main factor that can affect the test results is the presence of mutations in the ABL kinase domain. The test's accuracy can also be influenced by laboratory techniques and the quality of the sample.
What should I do if my test results are abnormal?
If your test results are abnormal, indicating imatinib resistance, it's essential to consult with your healthcare provider. They can guide you on the next steps, which may involve adjusting your treatment plan or considering alternative therapies.
What are the risks associated with this test?
The risks associated with the IRMA test are primarily those related to blood or bone marrow sample collection, which can include discomfort, bleeding, or infection at the puncture site.
Can medications influence the test results?
No medications are known to directly influence the results of the IRMA test. However, it's essential to inform your healthcare provider about all medications you are currently taking.
Is the IRMA test used only for diagnosing cancers?
No, the IRMA test is not used to diagnose cancer. It's specifically used to detect resistance to imatinib treatment in patients with certain types of cancers, like CML and GISTs.
What happens if the test result shows mutations in the ABL kinase domain?
If the test result shows mutations in the ABL kinase domain, it suggests that the patient's cancer has developed resistance to imatinib. This information can guide your healthcare provider in considering alternative treatment options or strategies.
Are there other tests typically performed alongside the IRMA test?
Yes, the IRMA test is often performed as part of a broader diagnostic workup. This can include a complete blood count (CBC), molecular testing for BCR-ABL fusion, and cytogenetic analysis. These tests together provide a comprehensive understanding of the disease and the response to treatment.
Who conducts the IRMA test?
This test is performed in a specialized laboratory and is supervised by a pathologist.
Is this test recommended for both men and women?
Yes, the IRMA test can be performed on both men and women, as CML and GISTs affect both genders.
Can this test be used for conditions other than cancers?
While the primary application of the IRMA test is in managing CML and GISTs, it may also be used in other specific clinical situations or for research purposes as determined by a healthcare provider.
Can lifestyle changes impact the test results?
Lifestyle changes do not directly influence the results of the IRMA test. The test results are primarily determined by the presence or absence of specific mutations in the ABL kinase domain.
Is the IRMA test painful?
The test itself is not painful. However, obtaining the blood or bone marrow sample for the test can cause some discomfort.
Can the IRMA test predict how well I will respond to treatment?
The IRMA test can help predict your response to imatinib treatment. If a mutation is detected, this indicates that your cancer has developed resistance to imatinib, and your healthcare provider may consider alternative treatments.
Understanding the Imatinib Resistance Mutation Analysis (IRMA) or Mutation Detection in the ABL Kinase Domain can be an important part of your cancer management strategy. This test can provide vital information for your healthcare provider, enabling them to make an accurate assessment of your response to imatinib therapy and adjust your treatment plan if necessary. As always, your healthcare provider's guidance is crucial in interpreting these results and deciding the next steps in your treatment journey.
Book Your Slot
Our Locations Near You in Hyderabad
3KM from Banjara Hills
1.9KM from Yusufguda
3KM from Madhura Nagar
5KM from Shaikpet